No Data
Ho\'s Ophthalmology: Report for the third quarter of 2024
Henshi Ophthalmology (301103.SZ): The net income in the first three quarters was 16.3755 million yuan, a year-on-year decrease of 83.53%.
GeLongHui October 28th | HaShi Ophthalmology (301103.SZ) released the third quarter report for 2024, the first three quarters of 2024, the company achieved revenue of 0.865 billion yuan, a year-on-year decrease of 8.40%; net income attributable to shareholders of the listed company was 16.3755 million yuan, a year-on-year decrease of 83.53%; net income after deducting non-recurring gains and losses was 14.7894 million yuan, a year-on-year decrease of 84.57%; basic earnings per share was 0.1045 yuan/share.
October 10 A-share Lightning Rod: tianfeng Securities: the company has no plans for merger and reorganization; changzhou almaden: shareholder Lin Jinkun intends to reduce shareholding by no more than 1.24%.
Hengshi Ophthalmology's shareholders Meixin Fund and Pengxin Fund intend to collectively reduce their holdings by no more than 0.83 million shares; Almaden's shareholder Lin Jinkun intends to reduce his shareholding by no more than 1.24%; Guangdong Dcenti Auto-Parts Stock's shareholder Taifeng International intends to reduce its shareholding by no more than 1%; ST Baili is suspected of violating disclosure regulations, and the CSRC has decided to initiate a case against the company and its controlling shareholder Wang Hairong; CSI All Share Investment Banking & Tianfeng Securities Co., Ltd. is not planning a merger or reorganization; *ST Zhongrun has terminated the private placement of stocks for the year 2022.
Hens Optometry (301103.SZ): Meixin Fund and Pengxin Fund plan to reduce their shareholdings by a total of no more than 0.83 million shares.
Gelonghui October 9th丨 Heshi Ophthalmology (301103.SZ) announced that Meixin Fund, Pengxin Fund plans to reduce the company's shares by a total of no more than 0.83 million shares through centralized auction trading on the stock exchange fifteen trading days after the disclosure date of this announcement within three months (i.e. from October 31, 2024 to January 30, 2025), accounting for 0.53% of the total share capital after excluding the shares in the repurchase special securities account.
Subdued Growth No Barrier To Liaoning He Eye Hospital Group Co., LTD. (SZSE:301103) With Shares Advancing 26%
Ho\'s Ophthalmology: 2024 Semi-Annual Report Summary
Liaoning He Eye Hospital Group (SZSE:301103) Could Be Struggling To Allocate CapitalNo Data
No Data
